3D Melanoma Cocultures as Improved Models for Nanoparticle-Mediated Delivery of RNA to Tumors.

cancer in vitro in vivo correlation (IVIVC) lipoplex mRNA nanoparticles tumor models tumor targeting

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
17 03 2022
Historique:
received: 21 12 2021
revised: 11 03 2022
accepted: 14 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 13 4 2022
Statut: epublish

Résumé

Cancer therapy is an emergent application for mRNA therapeutics. While in tumor immunotherapy, mRNA encoding for tumor-associated antigens is delivered to antigen-presenting cells in spleen and lymph nodes, other therapeutic options benefit from immediate delivery of mRNA nanomedicines directly to the tumor. However, tumor targeting of mRNA therapeutics is still a challenge, since, in addition to delivery of the cargo to the tumor, specifics of the targeted cell type as well as its interplay with the tumor microenvironment are crucial for successful intervention. This study investigated lipoplex nanoparticle-mediated mRNA delivery to spheroid cell culture models of melanoma. Insights into cell-type specific targeting, non-cell-autonomous effects, and penetration capacity in tumor and stroma cells of the mRNA lipoplex nanoparticles were obtained. It was shown that both coculture of different cell types as well as three-dimensional cell growth characteristics can modulate distribution and transfection efficiency of mRNA lipoplex formulations. The results demonstrate that three-dimensional coculture spheroids can provide a valuable surplus of information in comparison to adherent cells. Thus, they may represent in vitro models with enhanced predictivity for the in vivo activity of cancer nanotherapeutics.

Identifiants

pubmed: 35326474
pii: cells11061026
doi: 10.3390/cells11061026
pmc: PMC8946997
pii:
doi:

Substances chimiques

RNA, Messenger 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Federal Ministry of Education and Research
ID : 03FH8I02IA

Références

Semin Oncol. 2017 Jun;44(3):198-203
pubmed: 29248131
Mol Pharm. 2018 Feb 5;15(2):642-651
pubmed: 29232147
Nat Rev Drug Discov. 2018 Oct;17(10):751-767
pubmed: 30190565
Nature. 2016 Jun 01;534(7607):396-401
pubmed: 27281205
J Clin Med. 2021 Feb 01;10(3):
pubmed: 33535416
Biomaterials. 2011 Oct;32(29):7169-80
pubmed: 21724251
Front Oncol. 2021 Feb 05;10:621458
pubmed: 33614502
Biochem Pharmacol. 2013 Nov 15;86(10):1419-29
pubmed: 24035834
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499022
Front Mol Biosci. 2020 Feb 21;7:20
pubmed: 32154265
J R Soc Interface. 2011 Mar 6;8(56):345-68
pubmed: 20656740
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
J Proteome Res. 2014 Nov 7;13(11):5031-40
pubmed: 25322343
Adv Exp Med Biol. 2020;1219:51-74
pubmed: 32130693
Mol Pharm. 2018 Sep 4;15(9):3909-3919
pubmed: 30028629
Mol Oncol. 2021 Nov;15(11):3037-3061
pubmed: 33794068
BMC Cancer. 2019 Apr 29;19(1):402
pubmed: 31035967
PeerJ. 2017 Sep 5;5:e3754
pubmed: 28890854
Expert Opin Biol Ther. 2004 Aug;4(8):1285-94
pubmed: 15268662
Cancer Metastasis Rev. 2021 Jun;40(2):603-624
pubmed: 33870460
Int J Biochem Cell Biol. 2011 Apr;43(4):622-31
pubmed: 21216302
Nanomedicine (Lond). 2016 Oct;11(20):2723-2734
pubmed: 27700619
Nature. 2017 Mar 9;543(7644):248-251
pubmed: 28151488
J Physiol. 2021 Mar;599(6):1745-1757
pubmed: 33347611
Front Cell Neurosci. 2019 Feb 27;13:49
pubmed: 30873005
Mol Ther. 2017 Jun 7;25(6):1316-1327
pubmed: 28457665
Int J Mol Sci. 2020 Jun 27;21(13):
pubmed: 32605090
J Clin Oncol. 2001 Aug 15;19(16):3635-48
pubmed: 11504745
Methods Mol Biol. 2021;2265:173-183
pubmed: 33704714

Auteurs

Maximilian E A Schäfer (MEA)

Institute of Molecular and Cell Biology, Hochschule Mannheim, 68163 Mannheim, Germany.

Florian Keller (F)

Institute of Molecular and Cell Biology, Hochschule Mannheim, 68163 Mannheim, Germany.

Jens Schumacher (J)

Biopharmaceutical New Technology (BioNTech) SE, 55131 Mainz, Germany.

Heinrich Haas (H)

Biopharmaceutical New Technology (BioNTech) SE, 55131 Mainz, Germany.

Fulvia Vascotto (F)

Translational Oncology (TRON), University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

Ugur Sahin (U)

Biopharmaceutical New Technology (BioNTech) SE, 55131 Mainz, Germany.

Mathias Hafner (M)

Institute of Molecular and Cell Biology, Hochschule Mannheim, 68163 Mannheim, Germany.
Institute of Medical Technology, Heidelberg University and Hochschule Mannheim, 68163 Mannheim, Germany.

Rüdiger Rudolf (R)

Institute of Molecular and Cell Biology, Hochschule Mannheim, 68163 Mannheim, Germany.
Institute of Medical Technology, Heidelberg University and Hochschule Mannheim, 68163 Mannheim, Germany.
Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Hochschule Mannheim, 68163 Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH